You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameThiamylal
Accession NumberDB01154  (APRD00154)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state. (From Martindale, The Extra Pharmacopoeia, 30th ed, p919)
Structure
Thumb
Synonyms
5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid
5-Allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
5-Allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
dihydro-5-(1-Methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione
Thiamylal
Thioseconal
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SuritalNot Available
ThioseconalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Thiamylal sodium
ThumbNot applicableDBSALT001404
Categories
UNII01T23W89FR
CAS number77-27-0
WeightAverage: 254.349
Monoisotopic: 254.10889852
Chemical FormulaC12H18N2O2S
InChI KeyInChIKey=XLOMZPUITCYLMJ-UHFFFAOYSA-N
InChI
InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
IUPAC Name
5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione
SMILES
CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thiobarbituric acid derivatives. These are organic compounds containing a 2-thioxodihydropyrimidine-4,6(1H,5H)-dione skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentThiobarbituric acid derivatives
Alternative Parents
Substituents
  • Thiobarbiturate
  • 1,3-diazinane
  • Thiourea
  • Thiocarbonic acid derivative
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed for the production of complete anaesthesia of short duration, for the induction of general anaesthesia, and for inducing a hypnotic state.
PharmacodynamicsThiamylal, a barbiturate, is used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.
Mechanism of actionThiamylal binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Related Articles
AbsorptionRapidly absorbed (high lipid solubility).
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeAlthough no studies have been performed on humans, the half-life in cats is 14.3 hours.
ClearanceNot Available
ToxicityIntravenous LD50 in rat is 51 mg/kg.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5532
Blood Brain Barrier+0.9582
Caco-2 permeable-0.5361
P-glycoprotein substrateNon-substrate0.5169
P-glycoprotein inhibitor IInhibitor0.5544
P-glycoprotein inhibitor IINon-inhibitor0.9368
Renal organic cation transporterNon-inhibitor0.8887
CYP450 2C9 substrateNon-substrate0.8124
CYP450 2D6 substrateNon-substrate0.8589
CYP450 3A4 substrateNon-substrate0.7011
CYP450 1A2 substrateNon-inhibitor0.7869
CYP450 2C9 inhibitorNon-inhibitor0.5555
CYP450 2D6 inhibitorNon-inhibitor0.9131
CYP450 2C19 inhibitorNon-inhibitor0.6101
CYP450 3A4 inhibitorNon-inhibitor0.8138
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8282
Ames testNon AMES toxic0.6521
CarcinogenicityNon-carcinogens0.9047
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.7058 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9781
hERG inhibition (predictor II)Non-inhibitor0.8205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point132-133 °CPhysProp
water solubility49.4 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.23HANSCH,C ET AL. (1995)
logS-3.46ADME Research, USCD
pKa7.48SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0506 mg/mLALOGPS
logP3.11ALOGPS
logP2.92ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)7.2ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity70.64 m3·mol-1ChemAxon
Polarizability26.75 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Thiamylal can be decreased when combined with Abiraterone.
AcebutololThiamylal may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Thiamylal.
AcepromazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Thiamylal.
AcetazolamideThiamylal may increase the hypotensive activities of Acetazolamide.
adipiplonThe risk or severity of adverse effects can be increased when Thiamylal is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Agomelatine.
AldesleukinThiamylal may increase the hypotensive activities of Aldesleukin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Thiamylal.
AliskirenThiamylal may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiamylal.
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Thiamylal.
AmilorideThiamylal may increase the hypotensive activities of Amiloride.
AmineptineThe metabolism of Amineptine can be increased when combined with Thiamylal.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Thiamylal.
AmiodaroneThe metabolism of Thiamylal can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amitriptyline.
AmlodipineThiamylal may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amperozide.
AmrinoneThe metabolism of Amrinone can be increased when combined with Thiamylal.
Amyl NitriteThiamylal may increase the hypotensive activities of Amyl Nitrite.
ApraclonidineThiamylal may increase the hypotensive activities of Apraclonidine.
AprepitantThe metabolism of Thiamylal can be increased when combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with Aripiprazole.
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Thiamylal.
ArticaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Asenapine.
AtenololThiamylal may increase the hypotensive activities of Atenolol.
AzaperoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Azaperone.
AzelastineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Thiamylal.
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Thiamylal.
Azilsartan medoxomilThiamylal may increase the hypotensive activities of Azilsartan medoxomil.
AzimilideThe metabolism of Azimilide can be increased when combined with Thiamylal.
BaclofenThe risk or severity of adverse effects can be increased when Thiamylal is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Barbital.
BarnidipineThe metabolism of Barnidipine can be increased when combined with Thiamylal.
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Thiamylal.
BenazeprilThiamylal may increase the hypotensive activities of Benazepril.
BendroflumethiazideThiamylal may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenidipineThe metabolism of Benidipine can be increased when combined with Thiamylal.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Thiamylal.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Thiamylal is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be increased when combined with Thiamylal.
BetaxololThiamylal may increase the hypotensive activities of Betaxolol.
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Thiamylal.
BisoprololThiamylal may increase the hypotensive activities of Bisoprolol.
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Thiamylal.
BretyliumThiamylal may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
BrimonidineThiamylal may increase the hypotensive activities of Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brotizolam.
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Thiamylal.
BumetanideThiamylal may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiamylal.
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Thiamylal.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Thiamylal.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiamylal.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiamylal.
ButacaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiamylal.
CanagliflozinThiamylal may increase the hypotensive activities of Canagliflozin.
CandesartanThiamylal may increase the hypotensive activities of Candesartan.
CapecitabineThe metabolism of Thiamylal can be decreased when combined with Capecitabine.
CaptoprilThiamylal may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thiamylal.
CarbinoxamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carisoprodol.
CarteololThiamylal may increase the hypotensive activities of Carteolol.
CarvedilolThiamylal may increase the hypotensive activities of Carvedilol.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Thiamylal.
CeritinibThe serum concentration of Thiamylal can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Thiamylal can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiamylal.
ChlormezanoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chloroprocaine.
ChlorothiazideThiamylal may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiamylal.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorprothixene.
ChlorthalidoneThiamylal may increase the orthostatic hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Thiamylal can be decreased when combined with Cholecalciferol.
CilazaprilThiamylal may increase the hypotensive activities of Cilazapril.
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Thiamylal.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiamylal.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Thiamylal.
CitalopramThe risk or severity of adverse effects can be increased when Thiamylal is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clemastine.
ClevidipineThiamylal may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clonazepam.
ClonidineThiamylal may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Thiamylal.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiamylal.
ClotrimazoleThe metabolism of Thiamylal can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiamylal.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Thiamylal.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Thiamylal.
CyclizineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiamylal.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Thiamylal.
CyproheptadineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Cyproheptadine.
DabrafenibThe serum concentration of Thiamylal can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dantrolene.
DapagliflozinThiamylal may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiamylal.
DapoxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dapoxetine.
DarodipineThe metabolism of Darodipine can be increased when combined with Thiamylal.
DelavirdineThe metabolism of Thiamylal can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Thiamylal is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dexbrompheniramine.
DexmedetomidineThiamylal may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiamylal.
DextromoramideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Thiamylal.
DezocineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Thiamylal.
DiclofenamideThiamylal may increase the hypotensive activities of Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Thiamylal.
DifenoxinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydromorphine.
DiltiazemThiamylal may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dimenhydrinate.
DinutuximabThiamylal may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiamylal.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiamylal.
DipyridamoleThiamylal may increase the hypotensive activities of Dipyridamole.
DoramectinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Doramectin.
DosulepinThe metabolism of Dosulepin can be increased when combined with Thiamylal.
DotarizineThe metabolism of Dotarizine can be increased when combined with Thiamylal.
DoxazosinThiamylal may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Doxepin.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Thiamylal.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
DoxylamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Thiamylal is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Thiamylal.
DrotebanolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thiamylal.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Thiamylal.
EcgonineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Thiamylal is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Thiamylal is combined with Efavirenz.
EfonidipineThe metabolism of Efonidipine can be increased when combined with Thiamylal.
EmpagliflozinThiamylal may increase the hypotensive activities of Empagliflozin.
EnalaprilThiamylal may increase the hypotensive activities of Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Thiamylal.
EntacaponeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Entacapone.
EperisoneThe metabolism of Eperisone can be increased when combined with Thiamylal.
EplerenoneThiamylal may increase the hypotensive activities of Eplerenone.
EprosartanThiamylal may increase the hypotensive activities of Eprosartan.
EscitalopramThe risk or severity of adverse effects can be increased when Thiamylal is combined with Escitalopram.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Thiamylal.
EsmololThiamylal may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiamylal.
Etacrynic acidThiamylal may increase the hypotensive activities of Etacrynic acid.
EthanolThiamylal may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Thiamylal.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiamylal.
EthosuximideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethotoin.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiamylal.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiamylal.
EtoperidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etorphine.
EtravirineThe metabolism of Thiamylal can be decreased when combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ezogabine.
FelbamateThe serum concentration of Thiamylal can be increased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Felbamate.
FelodipineThiamylal may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fencamfamine.
FendilineThe metabolism of Fendiline can be increased when combined with Thiamylal.
FenfluramineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiamylal.
FexofenadineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Flibanserin.
FloxuridineThe metabolism of Thiamylal can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Thiamylal can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Thiamylal.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Thiamylal.
FlunitrazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Flunitrazepam.
FluorouracilThe metabolism of Thiamylal can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Thiamylal.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiamylal.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiamylal.
FluspirileneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Thiamylal can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluvoxamine.
FosinoprilThiamylal may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fospropofol.
FurosemideThiamylal may increase the hypotensive activities of Furosemide.
GabapentinThe metabolism of Gabapentin can be increased when combined with Thiamylal.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiamylal.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Thiamylal is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Thiamylal is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Thiamylal can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Glutethimide.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Thiamylal.
GuanfacineThiamylal may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Thiamylal.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Thiamylal.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiamylal.
HalothaneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Hexobarbital.
HydralazineThiamylal may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideThiamylal may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Thiamylal.
HydroflumethiazideThiamylal may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiamylal.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
HydroxyzineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Indalpine.
IndapamideThiamylal may increase the orthostatic hypotensive activities of Indapamide.
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Thiamylal.
IndinavirThe metabolism of Thiamylal can be decreased when combined with Indinavir.
IrbesartanThiamylal may increase the hypotensive activities of Irbesartan.
IrbesartanThe metabolism of Thiamylal can be decreased when combined with Irbesartan.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Thiamylal.
Isosorbide DinitrateThiamylal may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateThiamylal may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprineThiamylal may increase the hypotensive activities of Isoxsuprine.
IsradipineThiamylal may increase the hypotensive activities of Isradipine.
KetamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketobemidone.
KetoconazoleThe metabolism of Thiamylal can be decreased when combined with Ketoconazole.
LabetalolThiamylal may increase the hypotensive activities of Labetalol.
LacidipineThe metabolism of Lacidipine can be increased when combined with Thiamylal.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Thiamylal.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Thiamylal.
LeflunomideThe metabolism of Thiamylal can be decreased when combined with Leflunomide.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Thiamylal.
LevetiracetamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levetiracetam.
LevobunololThiamylal may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Thiamylal.
LevocabastineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiamylal.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Thiamylal.
LisinoprilThiamylal may increase the hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiamylal.
LosartanThiamylal may increase the hypotensive activities of Losartan.
LosartanThe metabolism of Thiamylal can be decreased when combined with Losartan.
LovastatinThe metabolism of Thiamylal can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiamylal.
Lu AA21004The risk or severity of adverse effects can be increased when Thiamylal is combined with Lu AA21004.
LumacaftorThe serum concentration of Thiamylal can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Thiamylal.
ManidipineThe metabolism of Manidipine can be increased when combined with Thiamylal.
MannitolThiamylal may increase the hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Maprotiline.
MecamylamineThiamylal may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Thiamylal.
MelperoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiamylal.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiamylal.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiamylal.
MetaxaloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Thiamylal.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methaqualone.
MethazolamideThiamylal may increase the hypotensive activities of Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiamylal.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Thiamylal.
MethsuximideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methsuximide.
MethyclothiazideThiamylal may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaThiamylal may increase the hypotensive activities of Methyldopa.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiamylal.
MetipranololThiamylal may increase the hypotensive activities of Metipranolol.
MetolazoneThiamylal may increase the orthostatic hypotensive activities of Metolazone.
MetoprololThiamylal may increase the hypotensive activities of Metoprolol.
MetyrosineThiamylal may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
MibefradilThe metabolism of Mibefradil can be increased when combined with Thiamylal.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiamylal.
MifepristoneThe serum concentration of Thiamylal can be increased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Thiamylal is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
MinoxidilThiamylal may increase the hypotensive activities of Minoxidil.
MirtazapineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Thiamylal.
MoexiprilThiamylal may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Thiamylal.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
NabiloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nabilone.
NadololThiamylal may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiamylal.
NebivololThiamylal may increase the hypotensive activities of Nebivolol.
NesiritideThiamylal may increase the hypotensive activities of Nesiritide.
NicardipineThiamylal may increase the hypotensive activities of Nicardipine.
NicardipineThe metabolism of Thiamylal can be decreased when combined with Nicardipine.
NifedipineThiamylal may increase the hypotensive activities of Nifedipine.
NiguldipineThe metabolism of Niguldipine can be increased when combined with Thiamylal.
NiludipineThe metabolism of Niludipine can be increased when combined with Thiamylal.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Thiamylal.
NimesulideThe metabolism of Nimesulide can be increased when combined with Thiamylal.
NimodipineThiamylal may increase the hypotensive activities of Nimodipine.
NisoldipineThiamylal may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Thiamylal.
NitroglycerinThiamylal may increase the hypotensive activities of Nitroglycerin.
NitroprussideThiamylal may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Olanzapine.
OlmesartanThiamylal may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Olopatadine.
OmeprazoleThe metabolism of Thiamylal can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Thiamylal.
OpiumThe risk or severity of adverse effects can be increased when Thiamylal is combined with Opium.
OrphenadrineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Thiamylal.
OsanetantThe risk or severity of adverse effects can be increased when Thiamylal is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiamylal.
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Thiamylal.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiamylal.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Thiamylal.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiamylal.
OxymorphoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paliperidone.
PapaverineThiamylal may increase the hypotensive activities of Papaverine.
ParaldehydeThiamylal may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Thiamylal.
ParoxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paroxetine.
PenbutololThiamylal may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiamylal.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiamylal.
PerampanelThe risk or severity of adverse effects can be increased when Thiamylal is combined with Perampanel.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Thiamylal.
PerindoprilThiamylal may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiamylal.
PethidineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Thiamylal.
PhenindioneThe metabolism of Phenindione can be increased when combined with Thiamylal.
PhenobarbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Thiamylal.
PhenytoinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Thiamylal.
PinaveriumThe metabolism of Pinaverium can be increased when combined with Thiamylal.
PindololThiamylal may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pizotifen.
PolythiazideThiamylal may increase the orthostatic hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pomalidomide.
PractololThe serum concentration of Practolol can be decreased when it is combined with Thiamylal.
PramipexoleThiamylal may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Prazepam.
PrazosinThiamylal may increase the hypotensive activities of Prazosin.
PregabalinThe metabolism of Pregabalin can be increased when combined with Thiamylal.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thiamylal.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Thiamylal.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Thiamylal.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Thiamylal.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Thiamylal.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiamylal.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Thiamylal.
PromethazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Promethazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Thiamylal.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Thiamylal.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Thiamylal.
PropoxycaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Propoxycaine.
PropranololThiamylal may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Thiamylal is combined with PSD502.
PyridoxineThe metabolism of Thiamylal can be increased when combined with Pyridoxine.
PyrimethamineThe metabolism of Thiamylal can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Quazepam.
QuetiapineThiamylal may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiamylal.
QuinaprilThiamylal may increase the hypotensive activities of Quinapril.
QuinethazoneThiamylal may increase the orthostatic hypotensive activities of Quinethazone.
QuinineThe metabolism of Thiamylal can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ramelteon.
RamiprilThiamylal may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiamylal.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiamylal.
ReserpineThiamylal may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiamylal.
RifampicinThe metabolism of Thiamylal can be increased when combined with Rifampicin.
RifapentineThe metabolism of Thiamylal can be increased when combined with Rifapentine.
RiociguatThiamylal may increase the hypotensive activities of Riociguat.
RisedronateThe metabolism of Risedronate can be increased when combined with Thiamylal.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiamylal.
RomifidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Romifidine.
RopiniroleThiamylal may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiamylal.
RotigotineThiamylal may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thiamylal.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Thiamylal is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiamylal.
SertindoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sevoflurane.
SildenafilThe metabolism of Thiamylal can be decreased when combined with Sildenafil.
Sodium oxybateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sodium oxybate.
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Thiamylal.
SorafenibThe metabolism of Thiamylal can be decreased when combined with Sorafenib.
SotalolThiamylal may increase the hypotensive activities of Sotalol.
SpironolactoneThiamylal may increase the hypotensive activities of Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiamylal.
SulfadiazineThe metabolism of Thiamylal can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Thiamylal can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Thiamylal can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiamylal.
SuvorexantThe risk or severity of adverse effects can be increased when Thiamylal is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tasimelteon.
TelmisartanThiamylal may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiamylal.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Thiamylal.
TerazosinThiamylal may increase the hypotensive activities of Terazosin.
TetrabenazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetrodotoxin.
ThalidomideThiamylal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Thiamylal.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Thiamylal.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiamylal.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Thiamylal.
TicagrelorThe metabolism of Thiamylal can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Thiamylal can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tiletamine.
TimololThiamylal may increase the hypotensive activities of Timolol.
TizanidineThiamylal may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Thiamylal.
TolbutamideThe metabolism of Thiamylal can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tolcapone.
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Thiamylal.
TopiramateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Topiramate.
TorasemideThiamylal may increase the hypotensive activities of Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiamylal.
TrandolaprilThiamylal may increase the hypotensive activities of Trandolapril.
TranilastThe metabolism of Tranilast can be increased when combined with Thiamylal.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiamylal.
TrazodoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Trazodone.
TriamtereneThiamylal may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiamylal.
TrichlormethiazideThiamylal may increase the orthostatic hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiamylal.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiamylal.
TrimethoprimThe metabolism of Thiamylal can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Thiamylal.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Thiamylal.
ValsartanThiamylal may increase the hypotensive activities of Valsartan.
ValsartanThe metabolism of Thiamylal can be decreased when combined with Valsartan.
VerapamilThiamylal may increase the hypotensive activities of Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vilazodone.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Thiamylal.
VoriconazoleThe metabolism of Thiamylal can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be increased when combined with Thiamylal.
XylazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Xylazine.
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Thiamylal.
ZafirlukastThe metabolism of Thiamylal can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiamylal.
ZiconotideThe metabolism of Ziconotide can be increased when combined with Thiamylal.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Thiamylal.
ZimelidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiamylal.
ZolazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Thiamylal.
ZonisamideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sugimura M, Kitayama S, Morita K, Imai Y, Irifune M, Takarada T, Kawahara M, Dohi T: Effects of GABAergic agents on anesthesia induced by halothane, isoflurane, and thiamylal in mice. Pharmacol Biochem Behav. 2002 May;72(1-2):111-6. [PubMed:11900777 ]
  4. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  5. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  6. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  7. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  8. Grasshoff C, Netzhammer N, Schweizer J, Antkowiak B, Hentschke H: Depression of spinal network activity by thiopental: shift from phasic to tonic GABA(A) receptor-mediated inhibition. Neuropharmacology. 2008 Oct;55(5):793-802. doi: 10.1016/j.neuropharm.2008.06.026. Epub 2008 Jun 21. [PubMed:18619475 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Inward rectifier potassium channel activity
Specific Function:
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward...
Gene Name:
KCNJ8
Uniprot ID:
Q15842
Molecular Weight:
47967.455 Da
References
  1. Eguchi S, Kawano T, Oshita S, Nakajo N: [Effects of propofol and thiamylal on nicorandil induced ATP-sensitive potassium channel activities in cultured rat aortic smooth muscle cells]. Masui. 2005 Apr;54(4):364-9. [PubMed:15852621 ]
  2. Kawano T, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, Kuroda Y, Nakaya Y: Molecular mechanisms of the inhibitory effects of propofol and thiamylal on sarcolemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology. 2004 Feb;100(2):338-46. [PubMed:14739809 ]
  3. Tsutsumi Y, Oshita S, Kitahata H, Kuroda Y, Kawano T, Nakaya Y: Blockade of adenosine triphosphate-sensitive potassium channels by thiamylal in rat ventricular myocytes. Anesthesiology. 2000 Apr;92(4):1154-9. [PubMed:10754636 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectific...
Gene Name:
KCNJ11
Uniprot ID:
Q14654
Molecular Weight:
43540.375 Da
References
  1. Kawano T, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, Kuroda Y, Nakaya Y: Molecular mechanisms of the inhibitory effects of propofol and thiamylal on sarcolemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology. 2004 Feb;100(2):338-46. [PubMed:14739809 ]
  2. Tsutsumi Y, Oshita S, Kitahata H, Kuroda Y, Kawano T, Nakaya Y: Blockade of adenosine triphosphate-sensitive potassium channels by thiamylal in rat ventricular myocytes. Anesthesiology. 2000 Apr;92(4):1154-9. [PubMed:10754636 ]
  3. Eguchi S, Kawano T, Oshita S, Nakajo N: [Effects of propofol and thiamylal on nicorandil induced ATP-sensitive potassium channel activities in cultured rat aortic smooth muscle cells]. Masui. 2005 Apr;54(4):364-9. [PubMed:15852621 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Sueyasu M, Fujito K, Shuto H, Mizokoshi T, Kataoka Y, Oishi R: Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40. [PubMed:10960410 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23